The PanTera consortium, born from the alliance between IBA, the world leader in particle accelerators, and the nuclear research center SCK CEN, is launching the large-scale production of actinium-225. This extremely rare radioisotope is seen as the key to a new generation of targeted cancer therapies. The goal: to treat more than 100,000 patients every year. KARL HUGO brings its high-precision industrial expertise to this Belgian technological challenge. The company will design essential reactor components as well as shielding, and will contribute to building the core of this future production line located in Mol.